Clinical trial Recruiting at 1 site Interventional Ages 40 and up

MiLOOP-assisted cataract surgery for dense cataracts

Official title: EVALUATION OF MILOOP LENS FRAGMENTATION DEVICE IN PHACOEMULSIFICATION FOR DENSE CATARACTS: A RANDOMIZED CONTROLLED TRIAL

Run by Universiti Kebangsaan Malaysia Medical Centre · NCT07898007 · Data updated 2026-11-12

In people with dense cataracts, this study tests whether using the miLOOP device during cataract surgery can protect corneal cells and reduce ultrasound energy, compared with standard surgery.

Quick facts

Study typeInterventional
Ages40 Years and up
SexAll
Enrollment68 (estimated)
SponsorUniversiti Kebangsaan Malaysia Medical Centre
Academic / other
Locations1 site (Cheras, Kuala Lumpur)
StatusRecruiting
StartedOctober 1, 2024
Main results expectedNovember 30, 2026
Study endsDecember 31, 2026
Registry record updatedOctober 27, 2026
Trial IDNCT07898007 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 40 and older with advanced dense cataracts (LOCS III grade 4 or higher) and adequate endothelial cell counts who consent to follow-up.

Probably not a fit

Patients with comorbidity or ocular conditions that increase risk or those not meeting endothelial cell or compliance criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial compares two cataract surgery approaches in adults with dense nuclear sclerosis. Participants are assigned to either the miLOOP-assisted method or standard phacoemulsification, with follow-up visits to monitor vision, endothelial cell health, and safety. The study aims to see if the miLOOP device reduces endothelial cell loss, lowers energy use, and improves visual outcomes without increasing risks. Outcomes include endothelial cell density, energy usage, safety events, and postoperative vision. The trial is conducted at a single center in Malaysia and is sponsored by Universiti Kebangsaan Malaysia Medical Centre.

Why it matters

Potential benefit: If successful, patients could experience better corneal health and clearer vision after dense cataract surgery with less energy exposure.

How similar studies have gone: Previous work with lens fragmentation devices suggests potential to reduce energy use and protect the cornea, but this exact miLOOP comparison for dense cataracts is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. age 40-year-old and above
2. capable to give informed consent
3. Advanced visually significant cataract with a minimum grade 4 nuclear sclerosis based on Lens Opacities Classification System III (LOCS III)
4. Best corrected visual acuity of 6/18 or worse using Snellen visual acuity chart
5. Willingness to cooperate with the doctors in the follow-up visits

Exclusion Criteria:

1. Eyes with significant anterior segment comorbidity besides an advanced cataract that could complicate the procedure including corneal opacity and zonulopathy
2. Presence of polar cataract
3. Co-existing glaucoma, cornea or retinal diseases
4. Presence of pseudoexfoliation
5. Poor pupil dilatation
6. Endothelial cell count (ECC) less than 2000 cells/mm2
7. Previous history of ocular surgery or trauma
8. History of uveitis
9. Complicated surgery such as intraoperative posterior capsule tear, zonular dialysis or conversion to extracapsular cataract extraction

Where it's running

  • Hospital Canselor Tuanku Muhriz
    Cheras, Kuala Lumpur, Malaysia
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.